the major prolongation is in the Gi phase of the cell cycle. When These studies also indicated that even patients with "benign monoclonal gammopathies" usually have over 100 g of the progeny of a single plasma cell clone in the body. In IgG myeloma the degree of skeletal involvement correlated significantly with the total number of tumour cells in the body. Bence Jones proteinuria, hypercalcemia, and short survival were also much more frequent in patients with over 2-0 x 1012 tumour cells. The variation in serum concentration of the M-component in different patients with similar numbers of myeloma cells is a result of the variation in the secretory rate of the myeloma clones in these patients. During the clinical course little more than four doublings of tumour cell number occur from the time of "early" diagnosis until death with far advanced bone disease.
The relation of the number of tumour cells to the natural history of disease and to the effects of treatment can be assessed by relating the total number of tumour cells in patients with early and advanced disease with their average life expectancy. Similar estimations can also be made by measuring the rate of change of the total body synthetic rate of M-component in patients who are untreated, those who are treated, and those who relapse during treatment.
If clonal doubling occurred at a constant exponential rate from its initiation one would calculate that the tumour had been present for over 16 years before clinical diagnosis. Though the concept of a simple exponential growth mode is attractive-and superficially might seem likely from evaluation of electrophoretic patterns-this mode of growth is rarely observed in tumour in animals, including various plasmacytomas, for in these growth slows increasingly as the tumour enlarges. This phenomenon can be described with a Gompertzian growth equation, which contains terms not only for the growth rate at any given time (A), which is a function of the number of tumour cells, but also a constant (a) that sets the degree of slowing of tumour growth.
Growth of Myeloma in Man
To define the actual mode of growth of myeloma in man we have done a detailed study using frequent electrophoretic, plasma volume, and tumour-cell number determinations. Together with Dr. Peter Sullivan we have recently designed very precise computer programmes which can indicate whether growth of myeloma is exponential or Gompertzian. These new techniques have shown already that in man myeloma does indeed grow in Gompertzian fashion and that the exponential models grossly overestimate the duration of the disease. Though a tremendous "iceberg" of tumour cell proliferation occurs asymptomatically before diagnosis, this growth appears to occur in under five years in the average patient. Possibly "benign monoclonal gammopathies" also grow rapidly at first, with retardation in the growth rate as the clone enlarges.
These studies have also been useful for analysing the effects of treatment of myelomatosis. Patients cases; in some of these, tests of subsequent serum samples using individually specific antisera were unab'e to eetect the monoclonal immunoglobulins, the monoclonal immunoglobulin spike (IgG, IgA, or IgM) disappearing within one month to two years. The monoclonal immunoglobulin level was less than 1 g/100 ml in all cases but one. Five of these nine patients were infants and only two were over 60 years. Three patients had primary immunodeficiency diseases. In a 20-year-old woman an IgG monoclonal immunoglobulin (2 5 g/100 ml) appeared three months after the onset of accute viral hepatitis and disappeared completely one month later. No antibody activity against Australia antigen was detected in this monoclonal immunoglobulin. We believe that these transient spikes of immunoglobulin probably reflect the production of a monoclonal antibody.
In some of our patients who were thoroughly studied the classical features of multiple myeloma developed progressively a few months or years after a monoclonal immunoglobulin had been detected. In these patients the level of immunoglobulin gradually increases, and even in slowly progressive cases myeloma could usually be suspected at the initial examination after careful studies of the bone marrow and immunoglobulins. In the vast majority of persons with a monoclonal immunoglobulin detected in the absence of overt myeloma the monoclonal immunoglobulin level of this remains stable over the years. This is true for most cases of monoclonal immunoglobulin associated with malignant lymphona or chronic lymphocytic leukaemia (where double spikes are not unfrequent). In these latter conditions the monoclonal immunoglobulin may be more often the consequence of the associated immunodeficiency rather than directly related to the lymphoid proliferation.
Patients without Myeloma
We have studied 58 patients with an IgG or IgA spike and without evidence of myeloma after thorough clinical, haematological, and x-ray examination at the time of detection and after a 3 to 8 years' follow-up (or complete postmortem study). In only two cases did the level of the monoclonal immunoglobulin rise significantly after it had been stable for some time; in them the level reached a new plateau and the patients did not develop myeloma subsequently. The levels of monoclonal immunoglobulin and of the normal serum immunoglobulins as well as the presence of Bence-Jones proteinuria are useful criteria at the first examination for distinguishing myeloma from benign monoclonal gammopathy. Nevertheless, among our 19 patients who did not develop myeloma after five years' follow-up, the initial level of monoclonal immunoglobulin was between 15 and 2*5 g/100 ml in three instances; normal immunoglobulin levels were decreased in four instances but remained stable throughout; and Bence-Jones proteinuria was present in five patients (always less than 0 2 g/24 hours). This series excludes patients with primary immunodeficiencies and malignant lymphomas. None of our patients in whom a monoclonal IgG or IgA was associated with ployclonal hyperimmunoglobulinaemia proved to have myeloma. On the other hand, this is not true for patients with IgM spikes, since high levels of IgG and IgA are not uncommon in malignant macroglobulinaemia.
In a few well-documented cases (especially in Waldenstrom's series) patients whose monoclonal immunoglobulin levels have been perfectly stable over many years may suddenly develop myeloma with a rapid increase of the monoclonal immunoglobulin level. We suggest that these cases constitute a separate entity from slowly progressive myeloma and that the presum- 
